Copay help by condition · Immune system, transplant and skin · read 2026-11-08

Chronic spontaneous urticaria (CSU): which charitable copay funds are open

The one fund we hold for Chronic spontaneous urticaria is closed or at capacity right now (read 2026-11-08).

Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.

If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.

Swipe to read across

Funds we hold for Chronic spontaneous urticaria, by the status each page gave on the day we read it.

What this is not. A record of what fund pages and FDA labels say, not advice and not a check of whether you qualify. US funds only. This page covers charitable funds from the organizations we read, the costs around a condition those funds pay for, and the drugs whose FDA label names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.

Every fund we hold for Chronic spontaneous urticaria

Closed or at capacityChronic spontaneous urticaria (CSU)

TotalAssist (Patient Advocate Foundation copay funds) · read 2026-11-08

Award level: $5,200Insurance supported: Any health insurance

The page lists the fund as Closed. Source page

Drugs whose FDA label names Chronic spontaneous urticaria

1 drug. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 1 has a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.

Drug	What the FDA label says	Manufacturer program	Medicare negotiated price
Xolair Omalizumab Every route for this drug	Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1. Label on openFDA, read 2026-11-10	Asthma Medication Assistance (Multiple Programs) Genentech Patient Foundation	selected by CMS for 2028; price not yet published

No broader or more specific condition page for this one.

Group: Immune system, transplant and skin. All conditions: the condition index. Fund board for every condition: charitable copay fund status.

What changed

First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.

This page as data

The same facts as JSON, each fund with its source URL and read date: chronic-spontaneous-urticaria.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.

Questions

Is there an open charitable copay fund for Chronic spontaneous urticaria?

As read on 2026-11-08, none of the 1 funds we hold for Chronic spontaneous urticaria say they are open. Funds reopen, so use the alert on this page.

Which organizations run funds for Chronic spontaneous urticaria?

TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.

Does an open fund mean I qualify?

No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.

How current is this page?

Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.